• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Arbutus Biopharma Corporation (Amendment)

    5/17/24 9:03:23 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABUS alert in real time by email
    SC 13D/A 1 sc13da114125002_05172024.htm AMENDMENT NO. 1 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 1)1

    Arbutus Biopharma Corporation

    (Name of Issuer)

    Common Shares, without par value

    (Title of Class of Securities)

    03879J100

    (CUSIP Number)

    DAVID SALANIC

    Joseph Kaplan

    WHITEFORT CAPITAL MANAGEMENT, LP

    12 East 49th Street, 40th Floor

    New York, New York 10017

     

    ELIZABETH GONZALEZ-SUSSMAN

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    Patricia Olasker

    Davies Ward Phillips & Vineberg LLP

    155 Wellington Street West

    Toronto, ON M5V 3J7

    (416) 863-0900

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    May 17, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 03879J100

      1   NAME OF REPORTING PERSON  
             
            Whitefort Capital Master Fund, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         12,867,967  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              12,867,967  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            12,867,967  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.8%  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 03879J100

      1   NAME OF REPORTING PERSON  
             
            Whitefort Capital GP, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         12,867,967  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              12,867,967  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            12,867,967  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.8%  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 03879J100

     

      1   NAME OF REPORTING PERSON  
             
            Whitefort Capital Management, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         12,867,967  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              12,867,967  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            12,867,967  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.8%  
      14   TYPE OF REPORTING PERSON  
             
            PN, IA  

      

    4

    CUSIP No. 03879J100

     

      1   NAME OF REPORTING PERSON  
             
            Whitefort Capital Management GP, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         12,867,967  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              12,867,967  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            12,867,967  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.8%  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    5

    CUSIP No. 03879J100

     

      1   NAME OF REPORTING PERSON  
             
            David Salanic  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            France  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         12,867,967  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              12,867,967  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            12,867,967  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.8%  
      14   TYPE OF REPORTING PERSON  
             
            IN, HC  

      

    6

    CUSIP No. 03879J100

     

      1   NAME OF REPORTING PERSON  
             
            Joseph Kaplan  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            AF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         12,867,967  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              12,867,967  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            12,867,967  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            6.8%  
      14   TYPE OF REPORTING PERSON  
             
            IN, HC  

      

    7

    CUSIP No. 03879J100

     

    The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned (“Amendment No. 1”). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein.

    Item 4.Purpose of Transaction.

    Item 4 is hereby amended to add the following:

    On May 17, 2024, the Reporting Persons issued a press release, including an open letter to the shareholders of the Issuer (the “Press Release”), to share their perspectives on maximizing value at the Issuer and ensure that the Board and fellow shareholders understand the urgency of these issues.

    In the Press Release, the Reporting Persons expressed their view that the Issuer should preserve the substantial value of the Company’s lipid nanoparticle (LNP) delivery technology patent infringement claims against Moderna, Inc. and Pfizer Inc./BioNTech SE. The Reporting Persons also noted that they were encouraged by Interim CEO and Board member Michael J. McElhaugh’s statement at a conference on May 14, 2024, that given the Issuer’s substantial cash balance ($138 million as of March 31, 2024) and sufficient liquidity through Q2 2026, the Issuer does not “anticipate the need to further utilize the ATM this year.”1 However, the Reporting Persons believe that the Issuer should firmly commit to cease any further share issuances for the foreseeable future, including under the Issuer’s at-the-market (ATM) program. Additionally, the Reporting Persons conveyed their view that the Issuer should be prepared to explore strategic options for its Hepatitis B (HBV) portfolio by yearend and judiciously allocate capital until then.

     

    In the Press Release, the Reporting Persons also shared that, in light of the high level of dilution that the Issuer’s shareholders have already suffered, they intend to vote Against Proposal #2 – approval of an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan at the Issuer’s Annual General and Special Meeting on May 22, 2024.

    The full text of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    Item 7.Material to be Filed as Exhibits.

    Item 7 is hereby amended to add the following exhibit:

    99.1Press Release, dated May 17, 2024.


    1 See https://wsw.com/webcast/jmp63/register.aspx?conf=jmp63&page=abus&url=https%3A//wsw.com/webcast/jmp63/abus/1673136.

     

    8

    CUSIP No. 03879J100

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: May 17, 2024

      Whitefort Capital Master Fund, LP
         
      By:

    Whitefort Capital GP, LLC

    General Partner

         
      By:

    /s/ David Salanic

        Name: David Salanic
        Title: Co-Managing Member
         
      By:

    /s/ Joseph Kaplan

        Name: Joseph Kaplan
        Title: Co-Managing Member

     

     

      Whitefort Capital GP, LLC
       
      By:

    /s/ David Salanic

        Name: David Salanic
        Title: Co-Managing Member
         
      By:

    /s/ Joseph Kaplan

        Name: Joseph Kaplan
        Title: Co-Managing Member

     

     

      Whitefort Capital Management, LP
       
      By:

    /s/ David Salanic

        Name: David Salanic
        Title: Co-Managing Partner
         
      By:

    /s/ Joseph Kaplan

        Name: Joseph Kaplan
        Title: Co-Managing Partner

     

    9

    CUSIP No. 03879J100

     

      Whitefort Capital Management GP, LLC
       
      By:

    /s/ David Salanic

        Name: David Salanic
        Title: Co-Managing Member
         
      By:

    /s/ Joseph Kaplan

        Name: Joseph Kaplan
        Title: Co-Managing Member

     

     

     

    /s/ David Salanic

      David Salanic

     

     

     

    /s/ Joseph Kaplan

      Joseph Kaplan

     

    10

     

    Get the next $ABUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABUS

    DatePrice TargetRatingAnalyst
    3/4/2022$5.50 → $6.00Buy
    Chardan Capital
    2/2/2022$4.00 → $5.00Hold → Buy
    Jefferies
    11/8/2021$7.00 → $9.00Market Outperform
    JMP Securities
    More analyst ratings

    $ABUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Chief Financial Officer Nguyen Tuan

      4/A - Arbutus Biopharma Corp (0001447028) (Issuer)

      4/1/25 5:47:47 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Nguyen Tuan

      4 - Arbutus Biopharma Corp (0001447028) (Issuer)

      3/31/25 4:24:03 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Nguyen Tuan

      3 - Arbutus Biopharma Corp (0001447028) (Issuer)

      3/31/25 4:21:38 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

      Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the presentation of five posters, including one late-breaker, highlighting imdusiran, its RNAi

      5/7/25 2:01:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

      Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued focus on efficient deployment of financial resources and personnel – terminated ATM program and implemented reduction of workforce by 57% in Q1 2025 Board has approved further changes to executive leadership team; including the appointment of Tuan Nguyen as Chief Financial Officer Strong financial position with cash, cash equivalents and investments in marketable securities of $123M WARMINSTER, Pa., March 27, 2025 (GLO

      3/27/25 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

      BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries. Genevant and Arbutus are seeking

      3/3/25 9:15:00 AM ET
      $ABUS
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Financials

    Live finance-specific insights

    See more
    • Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy Now dosing cHBV patients with AB-101 in Part 3 of the Phase 1a/1b clinical trial Cash runway into the fourth quarter of 2026Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a f

      11/6/24 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

      WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), ("Arbutus" or the "Company") a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast are as follows: • Q3 2024 Press Release:Wednesday, November 6, 2024 at 7:30 a.m. ET• Q3 2024 Conference Call/Webcast:Wednesday, November 6, 2024 at 8:45 a.m. ET   To dial-in for the conference call

      10/23/24 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I clinical trial demonstrated undetectable HBsAg in 33% of patients who were treated with 48 weeks of imdusiran and 24 weeks of IFN and in 67% of these patients with baseline HBsAg less than 1000 IU/mL Prioritizing imdusiran Phase 2b clinical development; eliminating HBV discovery efforts resulting in a reduction in workforce by 40% and extension of expected cash runway into the fourth quarter of 2026 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 01, 2024 (GLOBE

      8/1/24 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

      Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued focus on efficient deployment of financial resources and personnel – terminated ATM program and implemented reduction of workforce by 57% in Q1 2025 Board has approved further changes to executive leadership team; including the appointment of Tuan Nguyen as Chief Financial Officer Strong financial position with cash, cash equivalents and investments in marketable securities of $123M WARMINSTER, Pa., March 27, 2025 (GLO

      3/27/25 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

      WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski replaces Michael J. McElhaugh, the Company's Interim President and CEO, effective immediately. Ms. Androski will also serve as a member of the Company's board of directors. Ms. Androski is an MIT-trained biologist with nearly 30 years of experience in the areas of biotechnology, law and academia. She has served in a variety of roles at Roivant. She

      2/25/25 7:00:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

      WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that after a distinguished 38-year career, the Company's co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024. Dr. Sofia is a globally recognized, Lasker award-winning antiviral drug discovery and development scientist. "On behalf of the entire Company, I want to thank Mike, a renowned industry veteran, for his tremendous contribu

      5/2/24 7:25:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on Arbutus Biopharma with a new price target

      Chardan Capital reiterated coverage of Arbutus Biopharma with a rating of Buy and set a new price target of $6.00 from $5.50 previously

      3/4/22 8:38:50 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Biopharma upgraded by Jefferies with a new price target

      Jefferies upgraded Arbutus Biopharma from Hold to Buy and set a new price target of $5.00 from $4.00 previously

      2/2/22 5:11:07 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Arbutus Biopharma with a new price target

      JMP Securities reiterated coverage of Arbutus Biopharma with a rating of Market Outperform and set a new price target of $9.00 from $7.00 previously

      11/8/21 7:11:01 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    SEC Filings

    See more
    • Arbutus Biopharma Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Arbutus Biopharma Corp (0001447028) (Filer)

      5/7/25 6:00:14 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Biopharma Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Arbutus Biopharma Corp (0001447028) (Filer)

      4/23/25 6:00:14 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Arbutus Biopharma Corporation

      DEFA14A - Arbutus Biopharma Corp (0001447028) (Filer)

      4/4/25 4:06:26 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Arbutus Biopharma Corporation

      SC 13G/A - Arbutus Biopharma Corp (0001447028) (Subject)

      11/14/24 8:41:06 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Arbutus Biopharma Corporation

      SC 13G - Arbutus Biopharma Corp (0001447028) (Subject)

      6/10/24 4:50:25 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Arbutus Biopharma Corporation (Amendment)

      SC 13D/A - Arbutus Biopharma Corp (0001447028) (Subject)

      5/17/24 9:03:23 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care